# The Netherlands Cancer Institute

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/the-netherlands-cancer-institute/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 69.3 |
| Citations | 5,742,475 |
| City | Amsterdam |
| Country | NL |
| Description | The Netherlands Cancer Institute is a research organisation in Amsterdam, NL. OpenAlex records 29,793 works and 5,742,475 citations for it. 5,422 researchers list it as their most recent affiliation. |
| Homepage | https://www.nki.nl |
| OpenAlex ID | https://openalex.org/I2898336195 |
| Researchers | 5,422 |
| ROR ID | https://ror.org/03xqtf034 |
| Type | healthcare |
| Works | 29,793 |

## University collaborators

- [Oncode Institute](https://scholariq.org/institutions/oncode-institute/)
- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)
- [Institut Gustave Roussy](https://scholariq.org/institutions/institut-gustave-roussy/)
- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)
- [University Hospital Heidelberg](https://scholariq.org/institutions/university-hospital-heidelberg/)
- [Heidelberg University](https://scholariq.org/institutions/heidelberg-university/)
- [Royal Marsden Hospital](https://scholariq.org/institutions/royal-marsden-hospital/)

## University papers

Showing 12 of 85.

- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries](https://scholariq.org/papers/cross-validation-of-item-selection-and-scoring-for-the-sf-12-health-survey-in/)
- [Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers](https://scholariq.org/papers/risks-of-breast-ovarian-and-contralateral-breast-cancer-for-i-brca1-i-and-i/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations](https://scholariq.org/papers/translation-validation-and-norming-of-the-dutch-language-version-of-the-sf-36/)
- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal/)
- [Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease](https://scholariq.org/papers/homozygous-disruption-of-the-murine-mdr2-p-glycoprotein-gene-leads-to-a-complete/)
- [Systematic Review and Meta-analysis of Studies Reporting Urinary Continence Recovery After Robot-assisted Radical Prostatectomy](https://scholariq.org/papers/systematic-review-and-meta-analysis-of-studies-reporting-urinary-continence/)

## University researchers

- [Wim H. van Harten](https://scholariq.org/researchers/wim-h-van-harten/)
- [Sonja Levy](https://scholariq.org/researchers/sonja-levy/)
- [Z Al-Khayat](https://scholariq.org/researchers/z-al-khayat/)
- [Valesca P Retèl](https://scholariq.org/researchers/valesca-p-retel/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.